FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2102841229> ?p ?o ?g. }

• W2102841229 endingPage "428" @default.
• W2102841229 startingPage "427" @default.
• W2102841229 abstract "HomeHypertensionVol. 49, No. 3Cardiac Hypertrophy and the Wnt/Frizzled Pathway Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBCardiac Hypertrophy and the Wnt/Frizzled Pathway Oscar H. Cingolani Oscar H. CingolaniOscar H. Cingolani From the Johns Hopkins University School of Medicine, Baltimore, Md. Search for more papers by this author Originally published8 Jan 2007https://doi.org/10.1161/01.HYP.0000255947.79237.61Hypertension. 2007;49:427–428Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: January 8, 2007: Previous Version 1 The heart responds to sustained pressure overload with hypertrophy. Although at first glance this seems to be an adaptive mechanism by which the heart battles against increased workload, there is evidence that these “compensatory changes,” even early in the game, are different from the benign, truly adaptive response that occurs, for example, in athletes.1 In this group, hypertrophy is characterized by “physiological” myocyte growth and usually does not carry a poor prognosis. On the other hand, in hypertrophy associated with cardiovascular diseases, such as hypertension or aortic stenosis, increased expression of noncontractile proteins, such as collagen, as well as fetal isoforms of contractile proteins, take place, resulting in fibrosis, diastolic dysfunction, and, subsequently, heart failure. Therefore, differentiating the adaptive or “good” hypertrophy from the maladaptive or “bad” hypertrophy and their different pathways seems to be appropriate. Over the past decades, scientists have been studying left ventricular hypertrophy and its many intracellular mechanisms, trying to better understand the cellular changes that lead to pressure-activated hypertrophy and subsequent heart failure. It appears that some of these changes might be compensatory and some others, detrimental.1The Wnt signaling pathways play key roles in the differentiation, proliferation, death, and function of cells and, as a result, are involved in critical developmental, growth, and homeostatic processes. The Wnts are a family of genes/proteins. They have been linked to Alzheimer’s disease, aortic valve calcification, cancer, and diseases affecting bone.2 Control of the Wnt pathways is modulated by a number of proteins that either interact with the Wnt ligands directly or with the low-density lipoprotein-receptor related proteins 5 and 6 that, along with 1 of the different Frizzled proteins, function as coreceptors for the Wnt ligands2 (see Figure 6 in van de Schans et al3).Nusse and Varmus4 first described the int-1 gene, a proto-oncogene that induced tumors when the mouse mammary tumor virus was integrated into that locus. Subsequently it was shown that the Drosophilae homologue of int-1 was the segment polarity gene wingless, and the name “Wnt” was created as a contraction of wingless and int.2,5Currently in vertebrates there are ≥19 known Wnt genes. At the time this commentary is being written, there are 4 currently known Wnt signaling pathways: the canonical or Wnt/β-catenin pathway, the Wnt/Ca +2 pathway involving protein kinase A, the planar cell polarity pathway, and a pathway involving protein kinase C.2 The Wnt/β-catenin is the best studied of these pathways: association of Wnt-1 and members of the Frizzled protein family leads to activation of the disheveled (Dvl) protein. Activated Dvl inhibits glycogen synthase kinase-3β (GSK-3β), increasing cytosolic β-catenin levels as a consequence of decreased GSK-3β–mediated degradation. β-Catenin then interacts with members of the lymphoid enhancer factor/T-cell factor family of transcription factors in the nucleus, as well as other transcriptional factors involved in cell growth.2In this issue of Hypertension, van de Schans et al3 explored the effect of interruption of the Wnt/Frizzled pathway on the onset of cardiac hypertrophy. By subjecting mice lacking the Dvl-1 protein gene (Dvl−/−) to thoracic aortic coarctation (TAC), they were able to attenuate the development of cardiac hypertrophy when compared with their wild-type littermates (Dvl+/+), which were also subjected to TAC.Dsv functions upstream of GSK-3β, inhibiting it, so the final result in Dvl−/− mice was increased GSK-3β–mediated degradation of β-catenin, with the subsequent inhibition of hypertrophy signaling. The authors showed attenuation of cardiac mass index and myocyte cross-sectional area and decreased mRNA of hypertrophy biomarkers, such as ANP and BNP. Interestingly, they not only found a reduction in β-catenin levels after knocking out Dvl but also reduced amount of phosphorylated Akt, which is known to be downstream to Dvl but upstream of GSK-3β. Akt might also be involved in left ventricular hypertrophy activation through mechanisms that act independently from GSK-3β.6β-Catenin is known to regulate the proto-oncogenes c-myc, c-fos, c-jun, and cyclin D1. Of note, there was no difference in the expression of these genes between TAC Dvl−/− and TAC Dvl+/+. Although this can be explained by the late timing in which the gene expressions were determined (7 days rather than few hours after banding), the authors also hypothesize that there could be another β-catenin-independent mechanism(s), through which GSK-3β exerts its antihypertrophic effect. One interesting aspect of the present work is the fact that, in the absence of an insult (in this case, aortic banding), Dvl does not seems to play an important role in left ventricular hypertrophy, but it certainly does so when the heart is challenged with increased pressure workload.Some aspects still remain unanswered in the work under discussion. Although there was a significant attenuation of cardiac mass in the TAC Dvl−/− mice, and a tendency toward diminished cardiac interstitial fibrosis in this group, the latter was not significant. This deserves further research. Increased fibrosis seems to be key in differentiating between adaptive and maladaptive hypertrophy and the transition to diastolic and/or systolic heart failure.7,8 Because the authors have not provided us with functional data to assess how the intervention affected cardiac performance, it is difficult to conclude, analyzing the present results, which type of hypertrophy attenuation (adaptive versus maladaptive) might Wnt interruption be responsible for.In the last few years, the dogma that cardiac myocytes are terminally differentiated has been challenged by data showing that new, stem cell-derived cardiac cells are present in hearts after myocardial infarction or aortic stenosis.9 Because Wnts are involved in the morphological arrangement of cardiac myocytes in neonatal hearts,10 the hypothesis that Wnt/Frizzled activation might be necessary for new myocyte development for the heart to adapt to a new insult cannot be entirely ruled out. Furthermore, recent work suggests that Wnt/β-catenin signaling suppression might be involved in an animal model of right ventricular arrhythmogenic cardiomyopathy.11Cross-talking between the different Wnt pathways is another aspect that deserves further analysis. It has been suggested that Dvl might also be involved in calcium handling, protein kinase C and calcium-calmodulin kinase II,12 opening a wide spectrum of possibilities through which the hypertrophic program might be activated.The work by van de Schans et al3 offers new insight, showing that it is possible to attenuate pressure overload-induced hypertrophy by interruption of the Wnt/Frizzled pathway through mechanisms involving GSK-3β and Akt. This opens multiple avenues that deserve further investigation to better understand the cellular machinery that leads to left ventricular hypertrophy and heart failure.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.DisclosuresNone.FootnotesCorrespondence to Oscar H. Cingolani, Division of Cardiology, Department of Medicine, Johns Hopkins Hospital, 600 N Wolfe St/Carnegie 568, Baltimore, MD 21287. E-mail [email protected] References 1 Tarone G, Lembo G. Molecular interplay between mechanical and humoral signalling in cardiac hypertrophy. Trends Mol Med. 2003; 9: 376–382.CrossrefMedlineGoogle Scholar2 Johnson ML, Rajamannan N. Diseases of Wnt signaling. Rev Endocr Metab Disord. In press.Google Scholar3 van de Schans VAM, van den Borne SWM, Strzelecka AE, Janssen BJA, van der Velden JLJ, Langen RCJ, Wynshaw-Boris A, Smits JFM, Blankesteijn WM. Interruption of Wnt signaling attenuates the onset of pressure overload-induced cardiac hypertrophy. Hypertension. 2007; 49: 473–480.LinkGoogle Scholar4 Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell. 1982; 31: 99–109.CrossrefMedlineGoogle Scholar5 Rijsewijk F, Schuermann M, Wagenaar E, Parren P, Weigel D, Nusse R. The Drosophila homology of the mouse mammary oncogen int-1 is identical to the segment polarity gene wingless. Cell. 1987; 50: 649–657.CrossrefMedlineGoogle Scholar6 Zimmermann S, Moelling K. Phosphorylation and regulation of raf by Akt (protein kinase B). Science. 1999; 286: 1741–1744.CrossrefMedlineGoogle Scholar7 Weber KT. Are myocardial fibrosis and diastolic dysfunction reversible in hypertensive heart disease? Congest Heart Fail. 2005; 11: 322–324.CrossrefMedlineGoogle Scholar8 Gaasch WH, Zile MR. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med. 2004; 55: 373–394.CrossrefMedlineGoogle Scholar9 Anversa P, Kajstura J, Leri A, Bolli R. Life and death of cardiac stem cells: a paradigm shift in cardiac biology. Circulation. 2006; 113: 1451–1463.LinkGoogle Scholar10 Toyofuku T, Hong Z, Kusuya T, Tada M, Hori M. Wnt/frizzled-2 signaling induces aggregation and adhesion among cardiac myocytes by increased cadherin-β-catenin complex. J Cell Biol. 2000; 150: 225–241.CrossrefMedlineGoogle Scholar11 MacRae CA, Birchmeier W, Thierfelder L. Arrhythmogenic right ventricular cardiomyopathy: moving toward mechanism. J Clin Invest. 2006; 116: 1825–1828.CrossrefMedlineGoogle Scholar12 Shedahl LC, Slusarski DC, Pandur P, Miller JR, Kuhl M, Moon RT Dishevelled activates Ca+2 flux, PKC, and CamKII in vertebrate embryos. J Cell Biol. 2006; 161: 769–777.Google Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Yin C, Ye Z, Wu J, Huang C, Pan L, Ding H, Zhong L, Guo L, Zou Y, Wang X, Wang Y, Gao P, Jin X, Yan X, Zou Y, Huang R and Gong H (2021) Elevated Wnt2 and Wnt4 activate NF-κB signaling to promote cardiac fibrosis by cooperation of Fzd4/2 and LRP6 following myocardial infarction, eBioMedicine, 10.1016/j.ebiom.2021.103745, 74, (103745), Online publication date: 1-Dec-2021. Fu J, Yu Q, Li M, Hu C and Shi G (2020) Deleterious cardiovascular effect of exosome in digitalis‐treated decompensated congestive heart failure, Journal of Biochemical and Molecular Toxicology, 10.1002/jbt.22462, 34:5, Online publication date: 1-May-2020. Gupta S and Li L (2018) The role of Thymosin β4 in angiotensin II-induced cardiomyocytes growth, Expert Opinion on Biological Therapy, 10.1080/14712598.2018.1494718, 18:sup1, (105-110), Online publication date: 31-May-2018. Zhao Y, Wang C, Wang C, Hong X, Miao J, Liao Y, Zhou L and Liu Y (2018) An essential role for Wnt/β-catenin signaling in mediating hypertensive heart disease, Scientific Reports, 10.1038/s41598-018-27064-2, 8:1, Online publication date: 1-Dec-2018. Wang N, Huo R, Cai B, Lu Y, Ye B, Li X, Li F and Xu H (2016) Activation of Wnt/β-catenin signaling by hydrogen peroxide transcriptionally inhibits NaV1.5 expression, Free Radical Biology and Medicine, 10.1016/j.freeradbiomed.2016.04.003, 96, (34-44), Online publication date: 1-Jul-2016. Lu D, Bao D, Dong W, Liu N, Zhang X, Gao S, Ge W, Gao X and Zhang L (2015) Dkk3 prevents familial dilated cardiomyopathy development through Wnt pathway, Laboratory Investigation, 10.1038/labinvest.2015.145, 96:2, (239-248), Online publication date: 1-Feb-2016. Hlaing S, Garcia L, Contreras J, Norris K, Ferrini M and Artaza J 1,25-Vitamin D3 promotes cardiac differentiation through modulation of the WNT signaling pathway, Journal of Molecular Endocrinology, 10.1530/JME-14-0168, 53:3, (303-317) Fujiu K and Nagai R (2014) Fibroblast-mediated pathways in cardiac hypertrophy, Journal of Molecular and Cellular Cardiology, 10.1016/j.yjmcc.2014.01.013, 70, (64-73), Online publication date: 1-May-2014. Dawson K, Aflaki M and Nattel S (2013) Role of the Wnt-Frizzled system in cardiac pathophysiology: a rapidly developing, poorly understood area with enormous potential, The Journal of Physiology, 10.1113/jphysiol.2012.235382, 591:6, (1409-1432), Online publication date: 1-Mar-2013. Zheng Q, Chen P, Xu Z, Li F and Yi X (2013) Expression and redistribution of β-catenin in the cardiac myocytes of left ventricle of spontaneously hypertensive rat, Journal of Molecular Histology, 10.1007/s10735-013-9507-6, 44:5, (565-573), Online publication date: 1-Oct-2013. March 2007Vol 49, Issue 3 Advertisement Article InformationMetrics https://doi.org/10.1161/01.HYP.0000255947.79237.61PMID: 17210831 Originally publishedJanuary 8, 2007 PDF download Advertisement SubjectsAnimal Models of Human DiseaseDevelopmental BiologyHeart FailureHypertrophyRemodeling" @default.
• W2102841229 created "2016-06-24" @default.
• W2102841229 creator A5010772313 @default.
• W2102841229 date "2007-03-01" @default.
• W2102841229 modified "2023-10-16" @default.
• W2102841229 title "Cardiac Hypertrophy and the Wnt/Frizzled Pathway" @default.
• W2102841229 cites W1971727526 @default.
• W2102841229 cites W2000881336 @default.
• W2102841229 cites W2045369584 @default.
• W2102841229 cites W2067089329 @default.
• W2102841229 cites W2084771679 @default.
• W2102841229 cites W2104820453 @default.
• W2102841229 cites W2121130707 @default.
• W2102841229 cites W2134573562 @default.
• W2102841229 cites W2165781463 @default.
• W2102841229 cites W2168417210 @default.
• W2102841229 doi "https://doi.org/10.1161/01.hyp.0000255947.79237.61" @default.
• W2102841229 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17210831" @default.
• W2102841229 hasPublicationYear "2007" @default.
• W2102841229 type Work @default.
• W2102841229 sameAs 2102841229 @default.
• W2102841229 citedByCount "13" @default.
• W2102841229 countsByYear W21028412292013 @default.
• W2102841229 countsByYear W21028412292014 @default.
• W2102841229 countsByYear W21028412292016 @default.
• W2102841229 countsByYear W21028412292018 @default.
• W2102841229 countsByYear W21028412292020 @default.
• W2102841229 countsByYear W21028412292021 @default.
• W2102841229 crossrefType "journal-article" @default.
• W2102841229 hasAuthorship W2102841229A5010772313 @default.
• W2102841229 hasBestOaLocation W21028412291 @default.
• W2102841229 hasConcept C107300179 @default.
• W2102841229 hasConcept C126322002 @default.
• W2102841229 hasConcept C134018914 @default.
• W2102841229 hasConcept C137620995 @default.
• W2102841229 hasConcept C164705383 @default.
• W2102841229 hasConcept C167414201 @default.
• W2102841229 hasConcept C3018791406 @default.
• W2102841229 hasConcept C62478195 @default.
• W2102841229 hasConcept C71924100 @default.
• W2102841229 hasConcept C86803240 @default.
• W2102841229 hasConcept C95444343 @default.
• W2102841229 hasConceptScore W2102841229C107300179 @default.
• W2102841229 hasConceptScore W2102841229C126322002 @default.
• W2102841229 hasConceptScore W2102841229C134018914 @default.
• W2102841229 hasConceptScore W2102841229C137620995 @default.
• W2102841229 hasConceptScore W2102841229C164705383 @default.
• W2102841229 hasConceptScore W2102841229C167414201 @default.
• W2102841229 hasConceptScore W2102841229C3018791406 @default.
• W2102841229 hasConceptScore W2102841229C62478195 @default.
• W2102841229 hasConceptScore W2102841229C71924100 @default.
• W2102841229 hasConceptScore W2102841229C86803240 @default.
• W2102841229 hasConceptScore W2102841229C95444343 @default.
• W2102841229 hasIssue "3" @default.
• W2102841229 hasLocation W21028412291 @default.
• W2102841229 hasLocation W21028412292 @default.
• W2102841229 hasOpenAccess W2102841229 @default.
• W2102841229 hasPrimaryLocation W21028412291 @default.
• W2102841229 hasRelatedWork W1489434331 @default.
• W2102841229 hasRelatedWork W1514902666 @default.
• W2102841229 hasRelatedWork W1981311091 @default.
• W2102841229 hasRelatedWork W1994979890 @default.
• W2102841229 hasRelatedWork W2062621103 @default.
• W2102841229 hasRelatedWork W2102841229 @default.
• W2102841229 hasRelatedWork W2134573562 @default.
• W2102841229 hasRelatedWork W2370215344 @default.
• W2102841229 hasRelatedWork W3039857740 @default.
• W2102841229 hasRelatedWork W3081552745 @default.
• W2102841229 hasVolume "49" @default.
• W2102841229 isParatext "false" @default.
• W2102841229 isRetracted "false" @default.
• W2102841229 magId "2102841229" @default.
• W2102841229 workType "article" @default.